McClellan’s FDA Legacy? Decisive Role In Product Development Priorities
This article was originally published in The Gray Sheet
Executive Summary
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress